Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/1997

01-02-1997 | ORIGINAL ARTICLE

Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment

Authors: M. Hunault, D. Zhou, A. Delmer, S. Ramond, F. Viguié, M. Cadiou, J.-Y. Perrot, V. Levy, B. Rio, F. Cymbalista, R. Zittoun, J.-P. Marie

Published in: Annals of Hematology | Issue 2/1997

Login to get access
Metadata
Title
Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment
Authors
M. Hunault
D. Zhou
A. Delmer
S. Ramond
F. Viguié
M. Cadiou
J.-Y. Perrot
V. Levy
B. Rio
F. Cymbalista
R. Zittoun
J.-P. Marie
Publication date
01-02-1997
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/1997
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s002770050259

Other articles of this Issue 2/1997

Annals of Hematology 2/1997 Go to the issue

REVIEW ARTICLE

Activated T cells and cytokine-induced CD3+CD56+ killer cells

ORIGINAL ARTICLE

Acquired factor VIII inhibitors in nonhemophilic patients

CASE REPORT

Cytomegalovirus-associated myelodysplasia and thrombocytopenia in an immunocompetent adult

CASE REPORT

Myelodysplastic syndrome presenting as third malignancy after non-Hodgkin's lymphoma and osteosarcoma

ORIGINAL ARTICLE

Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression

ORIGINAL ARTICLE

Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits